SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 30th, 2021 • Q BioMed Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 30th, 2021 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 26th, 2021 (the “Effective Date”), by and between Q BIOMED, INC., a Nevada corporation, with headquarters located at c/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY 10017 (the “Company”), and PLATINUM POINT CAPITAL LLC, a Nevada limited liability company, with its address at 211 east 43rd Street, Suite 626, New York, NY 10017 (the “Buyer”).
AGREEMENTConvertible Debenture Amendment • July 30th, 2021 • Q BioMed Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 30th, 2021 Company Industry JurisdictionThis Amendment Agreement (the “Agreement”), dated as of July 22, 2021, is entered into by and between Q BIOMED INC., a company incorporated under the laws of the State of Nevada (the “Company”) and YA II PN, Ltd. (the “Buyer”), and amends the convertible debenture issued by the Company to the Buyer on December 23, 2020 (the “Convertible Debenture”) issued pursuant to a Securities Purchase Agreement entered into between the Company and the Buyer on December 23, 2020 (the “Securities Purchase Agreement”) and amends the Convertible Debenture.